Show simple item record

dc.contributor.authorSchmidinger, M
dc.contributor.authorDanesi, R
dc.contributor.authorJones, R
dc.contributor.authorMcDermott, R
dc.contributor.authorPyle, L
dc.contributor.authorRini, B
dc.contributor.authorNégrier, S
dc.date.accessioned2018-02-19T16:32:20Z
dc.date.issued2018-04
dc.identifier.citationFuture oncology (London, England), 2018, 14 (9), pp. 861 - 875
dc.identifier.issn1479-6694
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1332
dc.identifier.eissn1744-8301
dc.identifier.doi10.2217/fon-2017-0455
dc.description.abstractAxitinib is a potent, selective, vascular endothelial growth factor receptor inhibitor with demonstrated efficacy as second-line treatment for metastatic renal cell carcinoma. Analyses of axitinib drug exposures have demonstrated high interpatient variability in patients receiving the 5 mg twice-daily (b.i.d.) starting dose. Clinical criteria can be used to assess whether individual patients may benefit further from dose modifications, based on their safety and tolerability data. This review provides practical guidance on the 'flexible dosing' method, to help physicians identify who would benefit from dose escalations, dose reductions or continuation with manageable toxicity at the 5 mg b.i.d. dose. This flexible approach allows patients to achieve the best possible outcomes without compromising safety.
dc.formatPrint-Electronic
dc.format.extent861 - 875
dc.languageeng
dc.language.isoeng
dc.subjectHumans
dc.subjectCarcinoma, Renal Cell
dc.subjectImidazoles
dc.subjectIndazoles
dc.subjectVascular Endothelial Growth Factor A
dc.subjectProtein Kinase Inhibitors
dc.subjectDisease-Free Survival
dc.subjectDose-Response Relationship, Drug
dc.subjectKaplan-Meier Estimate
dc.subjectMolecular Targeted Therapy
dc.titleIndividualized dosing with axitinib: rationale and practical guidance.
dc.typeJournal Article
rioxxterms.versionofrecord10.2217/fon-2017-0455
rioxxterms.licenseref.startdate2018-04
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfFuture oncology (London, England)
pubs.issue9
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume14
pubs.embargo.termsNot known
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record